Phase II Study of SIRT and SERT With Chemotherapy in Patients With Recurrent /Metastatic Pancreatic Cancer
- Determine tumor response in patients with unresectable, newly diagnosed or recurrent
pancreatic cancer and liver metastases treated with selective internal radiotherapy
with yttrium Y 90 microspheres, selective external radiotherapy with tomotherapy, and
- Determine hepatic and systemic toxicity of this regimen in these patients.
- Determine the efficacy of this regimen, in terms of time to progression and survival,
in these patients.
OUTLINE: Patients receive fluorouracil IV continuously on days 1-4. Patients undergo
selective internal radiotherapy with yttrium Y 90 microspheres on day 2 and selective
external radiotherapy with tomotherapy on day 3.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Kenneth L. Pennington, MD
Goshen Health System
United States: Federal Government
|Center for Cancer Care at Goshen General Hospital||Goshen, Indiana 46526|